Spots Global Cancer Trial Database for AK104 in Neoadjuvant Treatment of Cervical Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: AK104 in Neoadjuvant Treatment of Cervical Cancer
Official Title: Phase II Study on AK104 in Neoadjuvant Treatment of Cervical Cancer
Study ID: NCT05227651
Conditions
Interventions
Study Description
Brief Summary: Phase II open label study to evaluate the safety and efficacy of AK104 (anti-PD-1 and CTLA-4 bispecific antibody) in neoadjuvant treatment of cervical cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Zhejiang Cancer Hospital, Hanzhong, Zhejiang, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
